RecruitingNot Applicable

Role of the Immune System in Preventing Laryngeal Cancer

Italy3 participantsStarted 2025-11-19

Plain-language summary

Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histopathological diagnosis of laryngeal dysplasia. * Age \>18 years and informed consent. Exclusion Criteria: * Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions. * Congenital or acquired immunodeficiency disorders. * Synchronous malignancies. * Immunosuppressive therapy. * Age \<18 years or absence of research consent.

What they're measuring

differences in TILs counts

Timeframe: 2 years

Trial details

NCT IDNCT07508319

SponsorEuropean Institute of Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Marta Tagliabue, MD

00390257489405 marta.tagliabue@ieo.it

View on ClinicalTrials.gov More Head & Neck Cancer trials